Loxicom

RSS

meloxicam

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 22/08/2016

Authorisation details

Product details
Name
Loxicom
Agency product number
EMEA/V/C/000141
Active substance
meloxicam
International non-proprietary name (INN) or common name
meloxicam
Species
  • Dogs
  • Cats
  • Cattle
  • Pigs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QM01AC06
Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic medicines.

Publication details
Marketing-authorisation holder
Norbrook Laboratories Limited
Revision
12
Date of issue of marketing authorisation valid throughout the European Union
10/02/2009
Contact address
Station Works
Newry
County Down
BT35 6JP
Northern Ireland
United Kingdom

Product information

26/07/2016 Loxicom - EMEA/V/C/000141 - IAIN/0026

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Anti inflammatory and antirheumatic products
  • non steroids

Therapeutic indication

Dogs

Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.

Cats

Alleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.

Cattle

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

Pigs

For use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

Horses

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.

For the relief of pain associated with equine colic.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating